Ex-Leerink Swann Banker Pleads Guilty to Insider Trading

FOCUSN Documents [Paper]Non-public annual audit reports filed by brokers or dealersAcc-no: 9999999997-13-004927 (34 Act) Size: 1 KB 2013-02-27 008-4853513030098 X-17A-5 Documents [Paper]FOCUS ReportAcc-no: 9999999997-13-002294 (34 Act) Size: 1 KB ...

CAMBRIDGE, Mass. Citigroup, Cowen and Company, LLC and Leerink Swann LLC will act as joint book-running managers for the offering. JMP Securities LLC and Wedbush Securities Inc. will act as co-managers for the offering. A registration statement ...

ST. PAUL, Minn.--(BUSINESS WIRE Leerink Swann LLC is acting as the sole book-running manager of the offering. JMP Securities LLC is acting as co-manager. The offering will be conducted pursuant to an effective shelf registration statement, including ...

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, has completed the acquisition of Actient Holdings LLC (Actient), a private urology specialty therapeutics company, for $585 million in upfront cash plus certain contingent ...

Actavis Inc. (ACT) Shares of Actavis surged 12 percent last week to $119.86 after Bloomberg News reported that it's in early-stage negotiations to acquire Warner Chilcott, which the companies later confirmed. The talks came after Actavis's ...

The following : Ambit Biosciences (AMBI), which is developing small molecule therapeutics for the treatment of acute myeloid leukemia, plans to raise $65 million by offering 4.6 million shares at a price range of $13.00 to $15.00. At the midpoint of ...

Receptos, Inc., a US-based biopharmaceutical company, has completed its initial public offering (IPO) of 5.2 million shares of common stock at a price of $14 per share for gross proceeds of $72.8 million. Update on May 8, 2013: Receptos has priced ...

Robin L. Washington Senior Vice President and Chief Financial Officer John C. Martin Chairman and Chief Executive Officer Norbert W. Bischofberger Executive Vice President, Research and Development and Chief Scientific Officer Kevin Young ...

The FDA put some lift under the wings of Raptor Pharmaceutical Corp., approving the orphan drug Procysbi (RP103, cysteamine bitartrate delayed-release) on its PDUFA date in the initial indication of nephropathic cystinosis (NC). The metabolic ...